Muscarinic cholinergic hyperactivity in schizophrenia : relationship to positive and negative symptoms
dc.contributor.author | Tandon, Rajiv | en_US |
dc.contributor.author | Shipley, James E. | en_US |
dc.contributor.author | Greden, John F. | en_US |
dc.contributor.author | Mann, Nancy A. | en_US |
dc.contributor.author | Eisner, William H. | en_US |
dc.contributor.author | Goodson, JoAnn | en_US |
dc.date.accessioned | 2006-04-10T14:51:01Z | |
dc.date.available | 2006-04-10T14:51:01Z | |
dc.date.issued | 1991 | en_US |
dc.identifier.citation | Tandon, Rajiv, Shipley, James E., Greden, John F., Mann, Nancy A., Eisner, William H., Goodson, JoAnn (1991)."Muscarinic cholinergic hyperactivity in schizophrenia : relationship to positive and negative symptoms." Schizophrenia Research 4(1): 23-30. <http://hdl.handle.net/2027.42/29522> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6TC2-45RCCW4-G/2/ad9365c3e5294293a6b8002b442189b3 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/29522 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2009253&dopt=citation | en_US |
dc.description.abstract | Based on the implication of increased muscarinic ACh activity in the production of negative symptoms, the association of decreasing cholinergic activity with positive symptoms, and the covariance of positive and negative symptoms in the psychotic phase of schizophrenia, a model of (DA) dopaminergic/(ACh) cholinergic interactions in schizophrenia was recently formulated. It suggests that DA/ACh balance is of central importance in schizophrenic pathophysiology and that muscarinic ACh activity increases in an attempt to maintain this balance in the face of increasing DA activity that occurs in the psychotic phase of the illness. The model further suggests that the muscarinic system exerts a damping influence on the emergence of positive symptoms associated with DA hyperactivity, but that this compensatory increase in muscarinic activity is accompanied by an intensification of negative symptoms. In the present study, we tested two important postulates of this model. We tested the prediction that muscarinic activity is increased in schizophrenia by comparing the effect of biperiden, an antimuscarinic M-1 agent, on REM latency in 12 drug-free schizophrenic inpatients and matched normal controls. We found that biperiden caused a smaller increase in REM latency in schizophrenic patients, suggesting that muscarinic activity is increased in schizophrenia. We tested the prediction that an anticholinergic agent would increase positive symptoms and decrease negative symptoms by studying the effect of 8 mg of biperiden/day for 2 days on positive and negative symptoms (assessed by the BPRS) in 30 medication-free schizophrenic inpatients. Biperiden produced a significant increase in positive symptoms (t = 6.36, DF = 29, P t = -2.05, DF = 29, P < 0.05). These findings suggest that central muscarinic activity is increased in the psychotic phase of schizophrenia and is relevant to the expression of positive and negative symptoms. | en_US |
dc.format.extent | 842663 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Muscarinic cholinergic hyperactivity in schizophrenia : relationship to positive and negative symptoms | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Psychology | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbtoplevel | Social Sciences | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Psychiatric Nursing, University of Michigan Medical Center, Ann Arbor, MI 48109-0120, U.S.A.; Schizophrenia Program, Ann Arbor, MI 48109-0120, U.S.A. | en_US |
dc.contributor.affiliationum | Psychiatric Nursing, University of Michigan Medical Center, Ann Arbor, MI 48109-0120, U.S.A.; Schizophrenia Program, Ann Arbor, MI 48109-0120, U.S.A. | en_US |
dc.contributor.affiliationother | Schizophrenia Program, Ann Arbor, MI 48109-0120, U.S.A. | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Ann Arbor, MI 48109-0120, U.S.A.; Sleep Diagnostic and Research Program, Ann Arbor, MI 48109-0120, U.S.A.; Schizophrenia Program, Ann Arbor, MI 48109-0120, U.S.A. | en_US |
dc.contributor.affiliationother | Department of Psychiatry, Ann Arbor, MI 48109-0120, U.S.A. | en_US |
dc.contributor.affiliationother | Schizophrenia Program, Ann Arbor, MI 48109-0120, U.S.A. | en_US |
dc.identifier.pmid | 2009253 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/29522/1/0000609.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0920-9964(91)90006-D | en_US |
dc.identifier.source | Schizophrenia Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.